The table below shows RECURSION PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$371.81M
-$359.17M
-$287.78M
-$83.52M
-$158.61M
-$45.40M
Capital expenditure
$6.47M
$13.70M
$11.96M
$37.06M
$39.80M
$5.83M
Investing cash flow
-$16.87M
$260.06M
-$10.23M
$193.25M
-$271.74M
-$8.74M
Dividends paid
-
-
-
-
RXRX operating cash flow (10-K history)
RECURSION PHARMACEUTICALS, INC. reported operating cash flow of -$371.81M for fiscal year 2025. That is down 3.5% from -$359.17M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$57.04M (FY 2019) to -$371.81M. Figures come from the company's audited annual reports as filed with the SEC.
